Page 36 - Viral Vector News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Raw materials play a vital role in the development of cell and gene (CGT) therapies.

What are some of dos and don’ts on starter materials for CGT manufacturing? Raw materials play a vital role in the development of cell and gene (CGT) therapies. Mike Brewer, director, global principal consultant, regulatory, bioproduction, Thermo Fisher Scientific, spoke to BioPharma-Reporter about some of dos and don’ts on starter materials for CGT manufacturing. His advice is particularly targeted at newer entrants to the CGT space, those at the at the preclinical stage, that might not have the same level of regulatory expertise that more established players...

Researchers at Children's Hospital of Philadelphia (CHOP) have developed a proof-of-concept treatment for blood disorders like sickle cell disease and beta-thalassemia that could raise hemoglobin levels by activating production of both fetal and adult hemoglobin.

Viral Vector & Plasmid DNA Manufacturing Market is expected to reach US$ 2,247.7 Mn by 2027 with Brammer Bio, Sanofi, Cardinal Health Inc., FUJIFILM Diosyn

INTRODUCTION Over the past few years, a number of advanced therapy medicinal products, including cell and gene therapies, have been developed and approved for the treatment of a variety of disease indications.New York, May 28, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, and Geographical Regions : Industry Trends and Global Forecasts, 2021-2030" - https://www.reportlinker.com/p06076414/?utm_source=GNW In fa...